Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have been given a consensus recommendation of “Buy” by the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $21.45.
Several analysts have weighed in on the company. UBS Group downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 target price on the stock. in a research note on Friday, January 5th. Mizuho reaffirmed a “neutral” rating and set a $18.00 target price (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research note on Wednesday, January 3rd. Leerink Swann reaffirmed a “market perform” rating and set a $15.00 target price on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Maxim Group downgraded Sucampo Pharmaceuticals to a “hold” rating in a research note on Monday, January 1st. Finally, ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 31st.
Shares of Sucampo Pharmaceuticals (SCMP) traded up $0.05 during trading on Friday, reaching $17.95. The company’s stock had a trading volume of 4,223,196 shares, compared to its average volume of 3,555,880. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market cap of $838.30, a P/E ratio of -5.36, a P/E/G ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $18.75.
In other news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the sale, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.13% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in shares of Sucampo Pharmaceuticals by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 423 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Sucampo Pharmaceuticals by 5.6% in the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 631 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Sucampo Pharmaceuticals by 4.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 790 shares during the last quarter. Thrivent Financial For Lutherans grew its holdings in shares of Sucampo Pharmaceuticals by 11.3% in the 2nd quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 1,550 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Sucampo Pharmaceuticals by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock worth $1,384,000 after acquiring an additional 1,690 shares during the last quarter. 64.62% of the stock is currently owned by institutional investors.
WARNING: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/23/sucampo-pharmaceuticals-inc-scmp-receives-21-45-consensus-price-target-from-brokerages.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.